CN1188137C - 红细胞生成素、具有激活epo受体能力或模拟epo活性的分子在制药中的用途 - Google Patents

红细胞生成素、具有激活epo受体能力或模拟epo活性的分子在制药中的用途 Download PDF

Info

Publication number
CN1188137C
CN1188137C CNB008065659A CN00806565A CN1188137C CN 1188137 C CN1188137 C CN 1188137C CN B008065659 A CNB008065659 A CN B008065659A CN 00806565 A CN00806565 A CN 00806565A CN 1188137 C CN1188137 C CN 1188137C
Authority
CN
China
Prior art keywords
epo
cisplatin
tumor
mice
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008065659A
Other languages
English (en)
Chinese (zh)
Other versions
CN1352561A (zh
Inventor
M·S·皮韦尔
D·F·西尔弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of CN1352561A publication Critical patent/CN1352561A/zh
Application granted granted Critical
Publication of CN1188137C publication Critical patent/CN1188137C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
CNB008065659A 1999-04-27 2000-04-24 红细胞生成素、具有激活epo受体能力或模拟epo活性的分子在制药中的用途 Expired - Fee Related CN1188137C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 1999-04-27
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents

Publications (2)

Publication Number Publication Date
CN1352561A CN1352561A (zh) 2002-06-05
CN1188137C true CN1188137C (zh) 2005-02-09

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008065659A Expired - Fee Related CN1188137C (zh) 1999-04-27 2000-04-24 红细胞生成素、具有激活epo受体能力或模拟epo活性的分子在制药中的用途

Country Status (18)

Country Link
US (3) US6171620B1 (https=)
EP (1) EP1212068A4 (https=)
JP (1) JP2002542296A (https=)
KR (1) KR100693796B1 (https=)
CN (1) CN1188137C (https=)
AU (1) AU781301B2 (https=)
BG (1) BG64940B1 (https=)
BR (1) BR0010082A (https=)
CA (1) CA2368618C (https=)
HU (1) HUP0200840A3 (https=)
IL (1) IL146012A0 (https=)
MX (1) MXPA01010899A (https=)
NO (1) NO20015227L (https=)
NZ (1) NZ514521A (https=)
PL (1) PL350918A1 (https=)
RU (1) RU2271829C2 (https=)
WO (1) WO2000064455A1 (https=)
ZA (1) ZA200108012B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232613T3 (es) 2000-04-26 2005-06-01 Cellegy Pharmaceuticals, Inc Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno.
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
EP2565195B1 (en) 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
US20110142834A1 (en) * 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Also Published As

Publication number Publication date
KR100693796B1 (ko) 2007-03-12
HUP0200840A3 (en) 2003-04-28
US6620779B2 (en) 2003-09-16
BG106057A (en) 2002-04-30
IL146012A0 (en) 2002-07-25
AU781301B2 (en) 2005-05-12
CA2368618A1 (en) 2000-11-02
EP1212068A1 (en) 2002-06-12
ZA200108012B (en) 2003-03-26
JP2002542296A (ja) 2002-12-10
AU4486300A (en) 2000-11-10
PL350918A1 (en) 2003-02-10
BG64940B1 (bg) 2006-10-31
US6171620B1 (en) 2001-01-09
MXPA01010899A (es) 2003-06-24
CN1352561A (zh) 2002-06-05
HUP0200840A2 (hu) 2002-07-29
NO20015227L (no) 2001-12-27
US20020198153A1 (en) 2002-12-26
NZ514521A (en) 2003-07-25
BR0010082A (pt) 2002-01-15
WO2000064455A1 (en) 2000-11-02
RU2271829C2 (ru) 2006-03-20
NO20015227D0 (no) 2001-10-25
US20010000730A1 (en) 2001-05-03
EP1212068A4 (en) 2007-03-14
US6426094B2 (en) 2002-07-30
KR20020000557A (ko) 2002-01-05
CA2368618C (en) 2011-03-01

Similar Documents

Publication Publication Date Title
CN1188137C (zh) 红细胞生成素、具有激活epo受体能力或模拟epo活性的分子在制药中的用途
JP5355856B2 (ja) Ｖｅｇｆアンタゴニストおよび抗増殖性薬剤の組成物ならびに癌の処置のためのその使用
EP0224885B1 (en) Antitumor composition.
CN1222294C (zh) 含吗啉蒽环类衍生物和抗癌剂的联合制剂
US20130122111A1 (en) Method for treatment of advanced solid tumors
WO2022106711A1 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN108892700A (zh) 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用
JP2009539916A (ja) ステージＩＶの悪性黒色腫の処置のための医薬品の製造のためのチモシンα１の使用
KR101964169B1 (ko) 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제
CN112168971B (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
Gonzalez et al. Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma
JPH0717518B2 (ja) 制ガン作用調節剤
Shi et al. Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice
CN121550252A (zh) 双二羧酸二氨络铂抗癌药物
Benasso et al. Analysis of 16 Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck: Implications for Treatment
CN119997967A (zh) C/EBP-β拮抗剂和免疫调节剂的使用
CN112168960A (zh) 抗VEGF抗体和抗ANG2抗体在制备治疗具有Ras突变的肿瘤的药物中的应用
WO2009062344A1 (en) Use of lymphotoxin for sensitizing tumor cells to chemotherapeutic drugs
US20160143929A1 (en) Administration of glufosfamide for the treatment of cancer
MXPA06008954A (en) Anti-cancer therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050209

Termination date: 20110424